Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
Patients currently on IOP reducing therapy: IOP greater than or equal to 25mmHg (Ltwo IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP greater than or equal to 30mmHg (two IOP determinations at pre-study separated by at least one hour).
You may not be if
History of acute angle closure or closed/barely open anterior chamber angle.
Current use of contact lenses.
Ocular surgery or argon laser trabeculoplasty (ALT) within three months prior to pre-study visit.
Ocular inflammation/infection occurring within three months prior to pre-study visit.
Hypersensitivity to benzalkonium chloride or to any other component of the study drug solutions.
Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement.
Patients with conditions in which treatment with B-blocking agents are contraindicated: cardiac failure, sinus bradycardia, second and third degree atrio-ventricular block.
Patients with conditions in which treatment with B-blocking agents are contraindicated: bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.
Inability to adhere to treatment/visit plan.
Have participated in any other clinical study within one month prior to pre-study visit.
